Prostate Cancer
An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positiveOligometastatic Prostate Cancer (OMPC) (CAAA617D12302)
- Details
ClinicalTrials.gov ID:
NCT05939414
Diagnosis Type:
NA
USOR Number:
- Address
,
P: